logo
logo
Owlet, Inc.

Owlet, Inc.

NYSE•OWLT
CEO: Mr. Kurt Workman
セクター: Healthcare
業種: Medical - Devices
上場日: 2020-11-05
Owlet, Inc. provides digital parenting solutions in the United States and internationally. The company's platform focuses on giving real-time data and insights to parents. It offers Dream Sock, a wearable infant health monitor equipped with pulse oximetry technology to track vitals signs, such as pulse rate, activity, oxygen, and sleep patterns; BabySat which is intended for infants with heightened health risk; Owlet Cam, a monitoring device in smartphones that offers video and audio, predictive sleep insights, and cry detections; and accessories, including Owlet Sleeper, as well as Duo and Dream Duo that combines Smart Sock with the Owlet Cam. The company was founded in 2012 and is headquartered in Lehi, Utah.
連絡先情報
3300 North Ashton Boulevard, Suite 300, Lehi, UT, 84043, United States
844-334-5330
www.owletcare.com
時価総額
$174.89M
PER (TTM)
-4.5
33.8
配当利回り
--
52週高値
$16.94
52週安値
$2.75
52週レンジ
58%
順位63Top 94.0%
1.8
F-Score
改良版 Piotroski 分析
6年ファンダメンタル
弱い • 1.8 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2020-2025

財務ダッシュボード

Q3 2025 データ

売上高

$31.99M+44.60%
直近4四半期の推移

EPS

$0.17-127.87%
直近4四半期の推移

フリーCF

-$2.43M-71.33%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Revenue Growth Strong Revenues $79.16M, up 37.5% (9M 2025). Driven by Dream Sock/Duo sales growth and new subscription.
Gross Margin Expansion Noted Gross Margin 51.7% (9M 2025), improving 2.5 points. Favorable product mix offset tariff cost pressures.
Operating Loss Significantly Reduced Operating loss narrowed to $(3.37M) (9M 2025). Significant improvement from $(12.81M) loss in prior period.
Cash Position Maintained Cash reserves $23.76M end of period. Financing provided $14.22M net cash inflow for nine months.

リスク要因

Going Concern Doubt Remains Historical losses and negative operating cash flow ($10.34M used 9M 2025) raise substantial doubt about viability.
Internal Control Deficiencies Noted Material weaknesses identified in control environment, personnel staffing, and segregation of journal entry duties.
Warrant Liability Volatility Impact Adjustment caused $23.80M loss for nine months ended September 30, 2025, significantly widening net loss.
Product Sourcing Tariff Exposure Vietnam/Thailand sourcing faces 19%-40% tariffs, potentially pressuring COGS and overall profitability metrics.

見通し

Recent Equity Financing Secured Completed October 2025 offering, raising $32.11M net proceeds for commercialization and R&D support efforts.
Debt Facilities Heavily Utilized ABL Line of Credit drew $18.62M; WTI Loan Facility holds $7.50M principal outstanding as of September 30, 2025.
Subscription Revenue Growing Owlet360 service launched January 2025, now contributing a growing minority portion of total revenues.
Major Litigation Settled Company paid $5.25M total liability for securities litigation during the third quarter of 2025, resolving claims.

同業比較

売上高 (TTM)

Lucid Diagnostics Inc.LUCD
$1.21B
+28885.2%
Owlet, Inc.OWLT
$99.66M
+26.8%
Anika Therapeutics, Inc.ANIK
$80.91M
-47.1%

粗利益率 (最新四半期)

Applied Therapeutics, Inc.APLT
100.0%
+0.0pp
Cardiff Oncology, Inc.CRDF
100.0%
+5842.4pp
MaxCyte, Inc.MXCT
92.4%
+16.1pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
SGHT$283.39M-6.1-61.6%35.0%
PROF$199.33M-5.0-86.8%0.7%
OWLT$174.89M-4.5126.8%33.3%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
16.0%
高成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
25%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年3月3日
|
EPS:-$0.13
|
売上高:$26.01M
財務レポート
財務データ
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月13日|
    売上高: $31.99M+44.6%
    |
    EPS: $0.17-127.9%
    予想を上回る

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月8日|
    売上高: $26.06M+25.9%
    |
    EPS: $-2.37+690.0%
    予想を下回る

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月8日|
    売上高: $21.10M+43.1%
    |
    EPS: $0.11-26.7%
    予想を上回る

  • Form 10-K/A - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年4月30日|
    売上高: $78.06M+44.5%
    |
    EPS: $-0.83+81.7%
    予想を下回る

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年3月11日|修正版データを参照

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月14日|
    売上高: $22.12M+140.9%
    |
    EPS: $-0.61-27.4%
    予想を下回る

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月14日|
    売上高: $20.70M+58.2%
    |
    EPS: $-0.30-70.9%
    予想を下回る

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月13日|
    売上高: $14.75M+37.4%
    |
    EPS: $0.15-109.7%
    予想通り